. 2012 Feb 14;2:8. doi: 10.1186/2191-219X-2-8

Table 2.

Biodistribution and tumor to non-target organ ratios for ⁶⁴Cu/NOTA-monomer and ⁶⁴Cu/NOTA-dimer 2

Organ	⁶⁴Cu/NOTA-monomer		⁶⁴Cu/NOTA-dimer 2

	30 min		30 min	120 min

	Unblocked	Blocked^a	Unblocked	Unblocked	Blocked^a
Blood	1.35 ± 0.47	12.72 ± 3.42	3.13 ± 0.67	1.34 ± 0.15	3.32 ± 2.78

Plasma	2.48 ± 0.63	21.69 ± 6.16	5.27 ± 1.27	2.45 ± 0.27	6.14 ± 4.89

Adrenal	4.29 ± 1.13	16.57 ± 0.37	9.23 ± 5.01	11.56 ± 4.91	3.63 ± 2.43

Fat	0.65 ± 0.54	3.22 ± 4.29	1.86 ± 0.81	0.68 ± 0.61	3.46 ± 2.74

Kidney	10.42 ± 1.29	75.13 ± 36.20	17.02 ± 6.24	26.37 ± 8.13	23.00 ± 5.37

Spleen	1.63 ± 1.82	3.29 ± 0.16	5.31 ± 1.43	5.50 ± 2.61	3.31 ± 0.95

Pancreas	5.10 ± 2.50	4.57 ± 2.65	4.60 ± 0.57	13.35 ± 7.38	1.43 ± 0.61^b

Liver	5.38 ± 8.12	8.12 ± 0.70	41.79 ± 5.58	23.11 ± 2.36	12.20 ± 2.78^b

Heart	1.05 ± 0.91	4.65 ± 0.33	4.42 ± 1.59	2.68 ± 0.13	1.58 ± 0.80

Lungs	1.77 ± 1.28	14.26 ± 1.58	7.22 ± 2.73	5.07 ± 1.58	34.42 ± 23.31

Muscle	0.40 ± 0.33	3.45 ± 2.06	1.59 ± 1.16	1.13 ± 0.62	1.41 ± 0.98

Bone	0.43 ± 0.46	1.52 ± 0.58	0.78 ± 0.21	0.83 ± 0.19	1.15 ± 0.44

Brain	0.08 ± 0.07	0.63 ± 0.09	0.38 ± 0.06	0.22 ± 0.05	0.16 ± 0.09

Tumor	1.79 ± 0.46	4.82 ± 0.91	3.95 ± 0.26	6.28 ± 2.87	3.25 ± 1.15

Tumor/blood	1.49 ± 0.41	0.38 ± 0.01^b	1.39 ± 0.30	4.09 ± 1.79	1.04 ± 0.60^b

Tumor/muscle	7.42 ± 3.17	1.59 ± 0.44^b	3.95 ± 1.98	4.46 ± 1.86	2.31 ± 1.46

Tumor/liver	2.07 ± 1.13	0.60 ± 0.13	0.10 ± 0.01	0.22 ± 0.07	0.24 ± 0.09

Tumor/kidney	0.17 ± 0.04	0.07 ± 0.01^b	0.28 ± 0.09	0.22 ± 0.11	0.12 ± 0.03

Tumor/pancreas	0.44 ± 0.17	1.18 ± 0.32^b	0.89 ± 0.11	0.36 ± 0.09	1.80 ± 0.39^b

Biodistribution and ratios are at 30 and 120 min post-injection. ^aBlocked by injecting 0.1 μmol of non-radiolabeled peptide together with the radiopeptide. ^bCo-injection significantly lowered the uptake of the same organ for the corresponding tracer (p < 0.05).